Published in Drug Deliv Transl Res on December 01, 2012
Vaginal drug delivery for the localised treatment of cervical cancer. Drug Deliv Transl Res (2017) 0.83
Simultaneous delivery of tenofovir and acyclovir via an intravaginal ring. Antimicrob Agents Chemother (2011) 1.38
Intravaginal ring delivery of the reverse transcriptase inhibitor TMC 120 as an HIV microbicide. Int J Pharm (2006) 1.32
Modulation of Viscoelasticity and HIV Transport as a Function of pH in a Reversibly Crosslinked Hydrogel. Adv Funct Mater (2009) 1.28
Advances in development, scale-up and manufacturing of microbicide gels, films, and tablets. Antiviral Res (2010) 1.24
Sustained release of the CCR5 inhibitors CMPD167 and maraviroc from vaginal rings in rhesus macaques. Antimicrob Agents Chemother (2012) 1.23
Design of a semisolid vaginal microbicide gel by relating composition to properties and performance. Pharm Res (2010) 1.19
An intravaginal ring for the simultaneous delivery of multiple drugs. J Pharm Sci (2012) 1.17
A 90-day tenofovir reservoir intravaginal ring for mucosal HIV prophylaxis. Antimicrob Agents Chemother (2012) 1.16
Microbicide delivery: formulation technologies and strategies. Curr Opin HIV AIDS (2008) 1.16
Development and evaluation of a vaginal ring device for sustained delivery of HIV microbicides to non-human primates. J Med Primatol (2009) 1.11
Non-aqueous silicone elastomer gels as a vaginal microbicide delivery system for the HIV-1 entry inhibitor maraviroc. J Control Release (2011) 1.05
Intravaginal rings as delivery systems for microbicides and multipurpose prevention technologies. Int J Womens Health (2013) 1.05
Novel approaches to vaginal delivery and safety of microbicides: biopharmaceuticals, nanoparticles, and vaccines. Antiviral Res (2010) 1.04
Designing preclinical perceptibility measures to evaluate topical vaginal gel formulations: relating user sensory perceptions and experiences to formulation properties. AIDS Res Hum Retroviruses (2013) 1.04
Vaginal rings for delivery of HIV microbicides. Int J Womens Health (2012) 1.04
Design of tenofovir-UC781 combination microbicide vaginal gels. J Pharm Sci (2012) 1.03
Vaginal delivery of the recombinant HIV-1 clade-C trimeric gp140 envelope protein CN54gp140 within novel rheologically structured vehicles elicits specific immune responses. Vaccine (2009) 1.03
A hot-melt extruded intravaginal ring for the sustained delivery of the antiretroviral microbicide UC781. J Pharm Sci (2011) 1.01
Expression profiling and functional analysis of Populus WRKY23 reveals a regulatory role in defense. New Phytol (2009) 1.00
Multipurpose prevention technologies: biomedical tools to prevent HIV-1, HSV-2, and unintended pregnancies. Infect Dis Obstet Gynecol (2011) 1.00
Multipurpose prevention technologies: products in development. Antiviral Res (2013) 1.00
Characterization of the rheological, mucoadhesive, and drug release properties of highly structured gel platforms for intravaginal drug delivery. Biomacromolecules (2009) 1.00
Genome-wide analysis of eukaryote thaumatin-like proteins (TLPs) with an emphasis on poplar. BMC Plant Biol (2011) 0.99
Sustained release of proteins from a modified vaginal ring device. Eur J Pharm Biopharm (2010) 0.96
Partial protection against multiple RT-SHIV162P3 vaginal challenge of rhesus macaques by a silicone elastomer vaginal ring releasing the NNRTI MC1220. J Antimicrob Chemother (2012) 0.95
Preclinical evaluation of anti-HIV microbicide products: New models and biomarkers. Antiviral Res (2010) 0.94
Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: optimisation by an artificial neural network. Int J Pharm (2010) 0.91
Pharmacokinetics and topical vaginal effects of two tenofovir gels in rabbits. AIDS Res Hum Retroviruses (2012) 0.90
Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. Vaccine (2011) 0.90
Pharmacokinetic and safety analyses of tenofovir and tenofovir-emtricitabine vaginal tablets in pigtailed macaques. Antimicrob Agents Chemother (2014) 0.89
Quantitative evaluation of a hydrophilic matrix intravaginal ring for the sustained delivery of tenofovir. J Control Release (2012) 0.87
A modified SILCS contraceptive diaphragm for long-term controlled release of the HIV microbicide dapivirine. Contraception (2012) 0.86
Controlled-release vaginal ring drug-delivery systems: a key strategy for the development of effective HIV microbicides. Ther Deliv (2010) 0.85
Microneedle mediated intradermal delivery of adjuvanted recombinant HIV-1 CN54gp140 effectively primes mucosal boost inoculations. J Control Release (2012) 0.85
Ethylene vinyl acetate intravaginal rings for the simultaneous delivery of the antiretroviral UC781 and contraceptive levonorgestrel. Drug Deliv Transl Res (2011) 0.82
Selection of an analytical method for evaluating bovine serum albumin concentrations in pharmaceutical polymeric formulations. J Pharm Biomed Anal (2009) 0.82
Characterization of silicone elastomer vaginal rings containing HIV microbicide TMC120 by Raman spectroscopy. J Pharm Pharmacol (2007) 0.82
Characterization of UC781-tenofovir combination gel products for HIV-1 infection prevention in an ex vivo ectocervical model. Antimicrob Agents Chemother (2012) 0.81
Approaches to improve the stability of the antiviral agent UC781 in aqueous solutions. Int J Pharm (2010) 0.81
Pharmacokinetics of UC781-loaded intravaginal ring segments in rabbits: a comparison of polymer matrices. Drug Deliv Transl Res (2011) 0.81
High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. Int J Pharm (2005) 0.80
Characterisation of protein stability in rod-insert vaginal rings. Int J Pharm (2012) 0.79
Preformulation and development of a once-daily sustained-release tenofovir vaginal tablet tablet containing a single excipient. J Pharm Sci (2013) 0.78
Preclinical evaluation of UC781 microbicide vaginal drug delivery. Drug Deliv Transl Res (2011) 0.78
Product Development Workshop 2013: HIV and Multipurpose Prevention Technologies. Antiviral Res (2013) 0.77
Modified silicone elastomer vaginal gels for sustained release of antiretroviral HIV microbicides. J Pharm Sci (2014) 0.77
Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. Vaccine (2012) 0.75
Development of liposome-based freeze-dried rods for vaginal vaccine delivery against HIV-1. J Control Release (2010) 0.75
Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. Eur J Pharm Sci (2012) 0.75
Lack of in vitro-in vivo correlation for a UC781-releasing vaginal ring in macaques. Drug Deliv Transl Res (2015) 0.75
Hot Melt Extruded and Injection Moulded Dosage Forms: Recent Research and Patents. Recent Pat Drug Deliv Formul (2015) 0.75
Development of polylactide and polyethylene vinyl acetate blends for the manufacture of vaginal rings. J Biomed Mater Res B Appl Biomater (2012) 0.75
Retro-engineering of liposomal vaccine adjuvants: role of a microarray-based screen. Vaccine (2009) 0.75
Correction: Musosal effects for tenofovir 1% gel. Elife (2015) 0.75
Investigating the feasibility of temperature-controlled accelerated drug release testing for an intravaginal ring. Eur J Pharm Biopharm (2013) 0.75